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Abstract
This chapter presents new views on thrombogenic risk factors, thrombophilia, and
thrombotic state of readiness preceding the thrombus formation. The modern methods
of laboratory diagnostics of thrombotic state of readiness are considered to initiate
thromboprophylaxis in patients irrespective of the presence of thrombophilia, as well
as certain thrombogenic risk factors.
Keywords: venous thromboembolism, thrombogenic risk factors, thrombophilia, hep‐
arin prophylaxis
1. Introduction
One of the most important problems in modern medicine, which has interdisciplinary signifi‐
cance is venous thromboembolism prophylaxis or VTE (deep vein thrombosis, DVT, and
pulmonary embolism, PE). This problem is associated with the high incidence of VTE around
the world, with a direct connection of this pathology to the disablement and mortality of people,
including those who underwent different invasive interventions and injuries (trauma, sur‐
gery, delivery) [1–7].
The association of tendency to thrombus formation with pregnancy complications and fetal
death syndrome is equally significant [8, 9]. This phase of women’s life is characterized with
blood coagulation activation related to physiological pregnancy and it progresses through
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gestation. Its rationale is associated with the need to reduce blood loss during delivery.
However, carrying of a pregnancy and the postpartum period are determined as confirmed
risk factors for venous thrombosis and pulmonary embolism with the incidence being 4–50
times higher than in non-pregnant women [10–12].
Besides the reduction of the survival rate of VTE and concomitant post-thrombotic syndrome,
it significantly shortens quality of life. The risk increases by 17 times after suffering from
venous thrombosis [13]. However, a 20-year cumulative incidence of post-thrombotic syn‐
drome after proximal deep vein thrombosis are about 40%.
Given the grandness of VTE for patients’ life, many researchers aimed not only at improving
methods of diagnostics and treatment of VTE (which is very crucial) but also at their antici‐
patory prophylaxis, prevention of primary or recurrent thrombotic events which is evidenced
by the international study, ENDORSE (Epidemiologic International Day for the Evaluation of
Patients at Risk of Venous Thrombosis in Acute Hospital Care Setting) [14].
Issues relating to thromboprophylaxis are represented in a number of national or international
guidelines on the prevention and treatment of VTE based on the intercenter research and
defining a standard tactic for thromboprophylaxis in obstetrics, oncology, cardiology,
traumatology and orthopedics, neurosurgery, urology, thermal injury, and also in patients at
high thrombogenic risk [15–21].
These are important, many-sided consolidated documents, which determine the modern level
of knowledge on this issue. However, their structure involves such risk factors as peculiarities
of scheduled operation and the type of anesthesia, a history of thrombosis, and inherited or
acquired likelihood to thrombosis for specific laboratory parameters. Anyway, these features
discussed in the documents, from the standpoint of evidence-based medicine, are relatively
significant for the prediction of risk for thrombosis and do not always answer the following
important questions: the rationale behind the prescription of anticoagulants in a specific
patient, optimal dosage, and the required duration of their use.
The modern practice of anticoagulant prescription still consider low molecular weight heparin
(LMWH) as a “gold standard” for the prevention of thrombosis in pregnancy, cancer, and
postoperative thromboprophylaxis [17, 22] even though the whole group of new oral
anticoagulants is used more often. Along with it, the discussion on the rationale behind
laboratory monitoring of anticoagulant effects from the stand point of safety of used doses is
continued and the determination of the effectiveness of the performed treatment that is
presented in the review by Hassouna [23].
Besides, there is an equivocal interpretation of concepts directly related to VTE, such as
thrombogenic risk factor, thrombophilia, and hypercoagulable state/syndrome, which
disorient clinicians who wish to understand the problem.
The objective of this chapter is to find the perspective approaches for diagnostic and consul‐
tative assistance of patients with VTE. These approaches will involve the definition of throm‐
bophilia and thrombogenic risk factors, as well as the state of thrombotic readiness when
considering the advisability of heparin prophylaxis from the view point of personalized
medicine.
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Most people, who are permanent or temporary carriers or are at risk of thrombosis, do not
suffer from thrombosis throughout their life, although they are likely to develop this disease
[24, 25]. However, the presence of thrombogenic risk factors is often compared with throm‐
bophilia, which leads to the over diagnosis of thrombophilia, especially during pregnancy and
concomitant polypragmasy.
2. Modern perspective on thrombophilia
The attention of many researchers has always been on the possible causes and conditions in
which thrombosis occurred. The risk of thrombosis is associated with trauma and surgical
routines in the area of large venous lines (hip surgery, pelvic organ surgery), with other types
of pathology and conditions which are predisposed to venous thrombosis (malignant tumors,
obesity, diabetes, heart failure, prolonged immobilization, etc.) accompanied by the activation
of blood coagulation. Taking this into consideration, in 1884, Rudolf Virchow reported that
venous thrombosis are the result of the presence of, at least, one of the three basic factors,
including (1) stasis of blood in lower extremity veins, (2) increased ability of blood to thrombus
formation—we understand it as thrombotic state of readiness, and (3) damaged vessel walls
[26]. It was determined that all the risk factors for venous thrombosis are carried out by these
important pathophysiological processes and that VTE, in their absence, does not usually
develop. In 1995, 30 years after the message of Egeberg (1965) [27] about the hereditary
deficiency of antithrombin III, the World Health Organization and the International Society
on Thrombosis and Hemostasis (ISTH) introduced the concept of thrombophilia as a state with
an unusual tendency to result in thrombosis with early age onset, burden family history,
severity of the thrombosis disproportionate to the known causal factors, and the presence of
thrombosis recurrence [28]. The emphasis was made on the types of congenital thrombophilia
associated with antithrombin III deficiency, factor V Leiden mutation (1691 G>A), prothrombin
mutation (20210 G>A), and decreased levels of protein C and S. On the other hand, only the
carriage of antiphospholipid antibodies in antiphospholipid syndrome (APS) associated with
both arterial and venous thrombosis as well as with a miscarriage is considered to be an
acquired thrombophilia.
In 2008, the version of the clinical practice recommended by the American College of Chest
Physicians (ACCP) on antithrombotic and thrombolytic therapy was published, it identified
thrombophilia as the presence of one or more of the following features, which included
antithrombin deficiency, protein C or S deficiency, APS resistance (factor Va resistance to
inactivate protein C), factor V Leiden mutation, prothrombin mutation (G20210A), hyperho‐
mocysteinemia, homozygous carriers of heat-labile variant of methylenetetrahydrofolate
reductase (MTHFR), the presence of antiphospholipid antibodies (aPL; lupus anticoagulant,
β2-glycoprotein I antibodies, or anticardiolipin antibodies) the increase in activity of factor VIII,
a reduced level of protein Z [29].
In 2013, the International Consensus Statement, Prevention and Treatment of Venous Throm‐
boembolism (guidelines according to scientific evidence) was published [15], where throm‐
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bophilia was determined as inherited or acquired state which shifts hemostatic balance toward
hypercoagulation, characterized by the predisposition to the first episode of VTE and high risk
of recurrence (Table 1).
Inherited thrombophilia  Acquired thrombophilia  Thrombophilia of mixed or unknown origin
Antithrombin deficiency
Protein C deficiency
Protein S deficiency
Factor V Leiden
Prothrombin 20210A
Disfibrinogenemia
Factor XIII 34val
Fibrinogen (G) 10034T
Non-O blood type
JAK 2
Factor IX Padua
Acquired deficiency of
natural coagulation inhibitors
Antiphospholipid syndrome
Myeloproliferative disease and
the presence of mutation JAK2V617F
Paroxysmal nocturnal hemoglobinuria 
High levels of factor VIII
High levels of factor IX
High levels of factor XI
High levels of fibrinogen
High levels of TAFI
Low levels of TFPI
Factor V resistance to APC in the absence of FVL
Hyperhomocysteinemia
High levels of PCI (PAI-3)
Notes: TAFI—thrombin activated fibrinolysis inhibitor, TFPI—tissue factor pathway inhibitor, PCI—protein C
inhibitor, PAI-3—plasminogen-activator inhibitor-3, FVL—Factor V Leiden, JAK 2—Janus kinase 2.
Table 1. Classification of hemostatic disorders associated with VTE according to their origin.
Risk factors Odds ratio 95% CI
Increases body mass index (BMI) by 15 kg/m2 1.08 1.05–1.11
Major surgery 18.95 9.22–38.97
Hospitalization for medical emergency 5.07 3.12–8.23
Trauma or fracture 4.56 2.46–8.46
Active malignancy 14.64 7.73–27.73
Neurological disease with the significant decrease in mobility 6.10 1.97–18.89
Pregnancy and postpartum period 4.24 1.30–13.84
Estrogen oral contraceptives 4.03 1.83–8.89
Hormonal replacement therapy in women 1.81 1.06–3.09
Note: CI—confidential interval.Data from Ref. [12].
Table 2. Independent risk factors for deep vein thrombosis and pulmonary embolism.
It is evident that peculiarities and clinical types of pathology mentioned in the table do not
involve many other causes predisposing to thrombosis, which also promote the development
of VTE—age, family or individual thrombotic history (e.g., after splenectomy), obesity,
dislipidemy, the use of venous catheter, pregnancy, the postpartum period, administration of
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contraceptives containing estrogen, severe injury or surgery, hypodynamia, physical and
psychological stress, active cancer, infection, autoimmune disorders, chronic heart failure,
diabetes mellitus, varicose disease of the lower extremities, dehydration, and many others.
These causes and their significance for the development of VTE were considerably described
in the fundamental work by Heit [12], based on the earlier work of the author [30], as well as
on the research by Barsoum et al. [31] (Table 2).
Considering this question, attention can be paid to the determination of clinical significance
of some risk factors predisposing VTE, in accordance with recent guidelines of the European
Society of Cardiology [17] (Table 3).
No Measure of significance Conditions promoting thromboembolism
1. Significant risk factors
(OR > 10)
Clot detachment; the first 3 months after
hospitalization with HF/AF; prosthetics
of lower extremities, a heavy injury,
the first 3 months after MI; prior
venous thromboembolic complications
2. Moderate risk factors
(OR = 2–9)
Arthroscopic surgery; autoimmune diseases;
hemotransfusion; chemotherapy; congestive
HF/PHD; HRT; malignant tumor;
oral contraceptives; thrombophilia;
stroke in anamnesis
3. Weak risk factors
(OR < 2)
Bed rest > 3 days;
diabetes; arterial hypertension;
long travel; age;
laparoscopic surgery; obesity;
pregnancy; varicose vein disease
Notes: OR—odds ratio, HF—heart failure, AF—atrial fibrillation, MI—myocardial infarction, PHD—pulmonary heart
disease, HRT—hormone replacement therapy.
Table 3. Gradation of the risk factors for venous thromboembolic complications in cardiac patients.
Thus, it can be observed that there are no significant differences between thrombogenic risk
factors and thrombophilia in modern guidelines and recommendations.
3. The question about the definition of “thrombogenic risk factor” and
“thrombophilia”
It is believed that thrombophilia precedes and accompanies thrombosis and fetal loss syn‐
drome [11, 32–34]. However, some clinicians deny the importance of genetic predisposition to
the development of thrombosis, observed in Table 1, which is explained by the fact that the
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connection between these phenomena is not always seen [35]. Indeed, the direct association
might be questionable, as evidenced by a number of publications, including a retrospective
family cohort study involving 723 first- and second-degree relatives of 150 patients with
venous thrombosis. The collected data in this study present interesting information about the
importance of thrombotic risk in patients with inherited defects in the physiological anticoa‐
gulation system, developability of which is relatively small. Thus, the cumulative lifetime
likelihood of thrombosis occurrence (penetrance) among the carriers of the most common
family thrombophilia (factor V Leiden mutation) is only about 10%.
It is also pointed out that the factor V Leiden mutation is not necessarily manifested by the
increased levels of D-dimer, polymorphism genes involved in the methionine metabolism by
hyperhomocysteinemia, and rare homozygote gene of plasminogen activator inhibitor type 1
(PAI-1), by the increased activity of PAI-1 and suppression of fibrinolytic reactions. These
thrombotic events are made possible in the presence of some mentioned gene polymorphisms,
but when and how far, cannot be predicted and it depends on additional risk factors in certain
cases, for example, dehydration, distress, or pregnancy. In this regard, there is a view that
thrombosis are multifactorial (complex) disease that occurs when a person with identified
thrombophilia is exposed to additional risk factors associated with the disease, due to personal
characteristics, or due to the external environment [12]. Thus, in accordance with the published
data, the risk of VTE among carriers of the factor V Leiden mutation increases with in particular
age; most cases occur at the age of 50–55 years [36–38]. The carriers of homozygous factor V
Leiden mutation might have a higher risk under the influence of the environment or other
genetic risk factors. The penetrance of thrombosis phenotype increases among patients with
multiple genetic defects (e.g., concomitant deficiency of antithrombin, protein C or S). The
same indicator depends on the clinical effects of acquired risk factors, such as the use of
combined oral contraceptives, pregnancy, or surgery. In particular, the relative risk of the VTE
among the carriers of heterozygous factor V Leiden mutation with estrogen contraceptives
increases by 30 times [38, 39].
In general, the presence of inherited thrombophilia increases the risk of VTE by seven times
[40]. At the same time, as earlier mentioned (see Table 2), a number of acquired thrombogenic
risk factors (major surgery, endoprosthesis replacement of large joints, hospitalization due to
medical emergency, active cancer, etc.) without combination with inherited thrombophilia
have no less prognostic value for VTE occurrence.
Despite this important and interesting information, it is still not clear—the difference between
thrombogenic risk factors and thrombophilia.
From our point of view to avoid confusion, separation of terms “thrombogenic risk factors”
and “thrombophilia” can be based (in a similar way) on the example referring APS to throm‐
bophilia.
According to the recommendations of the ISTH, adopted in Sapporo (1998) and Sydney (2006)
[41], diagnosis of APS is believed to be reliable when, at least, one or more clinical manifesta‐
tions of this pathology (vascular thrombosis, pregnancy failure) are combined with the results
Anticoagulation Therapy52
of special laboratory tests (effects of lupus anticoagulant, antiphospholipid antibodies in the
diagnostic titer; Table 4).
Clinical criteria   Laboratory criteria
1. Vascular thrombosis
- One or more cases of arterial and/or
venous thrombosis or thrombosis of small
vessels in any organ or tissue.
- Thrombosis must be confirmed by
Doppler examination or histologically.
- There should be morphologically symptoms of
thrombosis without significant inflammation of
vessel walls.
2. Pregnancy failure
- Three or more unexplained cases of miscarriage up
to 10 weeks of gestation excluding anatomic,
genetic, hormonal causes and chromosomal
abnormalities;
- One or more cases of intrauterine death of a normal
fetus after 10 weeks of gestation;
- One or more cases of premature birth of a fetus after
less than 34 weeks of gestation occurring with
evident fetoplacental insufficiency or severe gestosis
  
1. Anticardiolipin antibodies
- The presence of isotypes IgG and IgM in high titers in
two or more studies with an interval of not less than 12
weeks.
- Identifying antibodies IgG, IgM to β2-glycoprotein I
by a standardized ELISA test.
2. Lupus anticoagulant
- It is found in two or more consecutive tests with an
interval of not less than 12 weeks
Table 4. Diagnostic criteria for diagnosis of antiphospholipid syndrome.
We suggest an extension of this approach (involving the combination of certain thrombogenic
risk factors with thrombosis or fetal loss syndrome) to the methodology of thrombophilia
diagnostics. The presence of certain causes predisposing to thrombosis in patients without
their clinical realization cannot be referred to as thrombophilia (Figure 1).
We consider that thrombophilia is essentially not a disease, but it is a pathological condition
caused by a combination of risk factors, realized by the development of thrombosis (thrombo‐
ses), which can be obtained according to the individual medical history. It may be inherited
or associated with the disease (e.g., cancer), drug intake (e.g., oral contraceptives, erythropoi‐
esis stimulating agents), or state of health (e.g., pregnancy, postpartum period). It is very
important to understand and accept this position because susceptibility to the disease does not
imply the presence of indications for primary or secondary prophylaxis or treatment [12].
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In addition to APS, according to the same criteria, Trousseau’s syndrome (migrating venous
thrombosis in the presence of cancer procoagulant), Moschkowitz’s syndrome (arterial
microthrombosis on the background of circulation of large multimers of von Willebrand factor
in blood, in the presence of metalloproteinase ADAMTS-13 deficiency), heparin-induced
thrombocytopenia of 2 type—HIT-2 (subcutaneous and systemic venous thrombosis in the
presence of antiheparin antibodies) and warfarin necrosis or Legg’s disease on the background
of inherited protein C deficiency can be referred to as thrombophilia. We consider that this list
is not complete.
Thus, it is suggested:
1. Syndromic approach to the diagnostics of thrombophilia.
2. Identification of all causes promoting the development of VTE (including known states
identified as thrombophilia) as thrombogenic risk factors.
Figure 1. Hypothesis about the interaction of thrombogenic risk factors, thrombotic readiness, and thrombophilia in
the development of thrombosis and fetal loss syndrome.
Presently, there are more than 100 variants of thrombophilia and various thrombogenic risk
factors described, which are capable in their combination to lead to a vascular catastrophe [12,
42, 43]. However, it is believed as insufficient to divide them into hereditary (congenital) and
acquired. From the point of view of personalized thromboprophylaxis, the classification of
thrombogenic risk factors should be based on the duration of exposure to a human body and
controllability by the patient or by means of modern medicine, to reduce the probability of
VTE.
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Uncontrollable risk factors, such as age, sex, family and personal thrombotic history, the
carriage of thrombogenic mutations, non-O blood group, and several others, are not amenable
to correction and accompany the person for life. The temporary and controllable risk factors
are much more numerous, which, in turn, can be divided into, associated with lifestyle (e.g.,
bad habits, obesity, hypodynamia (including long flight), mental distress and physical
overload, as well as dehydration during sporting activities), individual characteristics
(pregnancy, postpartum period), caused by a disease (trauma, cancer, sepsis, myocardial
infraction and stroke, diabetes, atherosclerosis, arterial hypertension, cardiac rhythm disor‐
ders, HIV infection), and iatrogenic—caused by surgery and prescription of some medicine
with estrogen therapy, progesterone therapy, selective estrogen receptor modulators, chemo‐
therapy, erythropoietin administration, in some cases with usage of heparin or coumarins.
Controllability of these risk factors is different and might be considered individually in all
cases, from the point of view of both etiology and pathogenesis of thrombosis. If modern
possibilities of medicine are limited to radical correction of risk factors existing for life or
permanently, then, for example, substitution of deficiency of physiological anticoagulants,
heparin prophylaxis, usage of folic acid with correction of elevated levels of homocysteine in
blood, blood viscosity reduction during dehydration or erythrocytosis, and other types of
pathogenetic therapy allow the modification of identified thrombogenic risk factors and a
reduction in the probability of clinical manifestation of VTE.
Nowadays, the mentioned recommendations do not show the association between the
presence of “thrombophilia”, “thrombogenic risk factors”, and blood coagulation activation
for known laboratory markers. However, it can be suggested that blood coagulation activation
is the main condition for thrombus formation and a prerequisite for heparin prophylaxis.
4. Thrombotic readiness
The terms “thrombophilia” and “hypercoagulability” are often considered by many authors
as synonyms, but in real sense, these notions are different. Hypercoagulation or “hypercoa‐
gulation syndrome/state” is a laboratory phenomenon by which “in vitro” with the help of
special methods of hemostasis system analysis platelet activation and the process of fibrin
formation, and in some cases, inhibition of fibrinolytic reactions are recognized. Hypercoagu‐
lation can be promoted by drugs commonly used to treat bleeding in hemophilia, sepsis,
inflammation, surgery, hemostasis, and atherosclerosis as well as by many other factors and
conditions. However, it can appear in the analysis of hemostatic parameters—in the case of
warfarin skin necrosis, associated with congenital protein C deficiency due to treatment with
coumarins, heparin-induced thrombocytopenia with heparin prescription, and effects of lupus
anticoagulant peculiar to antiphospholipid syndrome. Consequently, the notions such as
“hypercoagulation syndrome” and “hypercoagulation state” do not meet the essence of the
pathological process and should therefore be considered obsolete.
We proposed an alternative, a clinically justifiable notion of “the state of thrombotic readiness”,
which can combine laboratory detected hypercoagulation or hypocoagulation (in cases of APS,
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HIT-2, warfarin necrosis, and others), increased levels of intravascular coagulation markers
due to the excessive thrombin generation, and also a number of clinical signs of prethrombosis.
Accordingly, a realization of this readiness with the continued risk factors and their multipli‐
cation (e.g., surgery, injury, inflammation, emergency, immobilization, heart failure, dehy‐
dration, distress, intake of estrogens, etc.) is manifested by the vascular catastrophe in
Figure 1. Thus, the state of thrombotic readiness might be formed by cooperation of various
thrombogenic risk factors and directly precedes thrombosis, and also accompanies it in its
absence or the low efficiency of antithrombotic prophylaxis and therapy.
Based on the study of their functional activity (in an aggregometer or platelet function analyzer,
PFA-100/PFA-200) or by increased expression of β-thrombomodulin, as well as III and IV
platelet factors, platelet activation can be attributed to the laboratory markers of the state of
thrombotic readiness. No less significant indicator of such readiness is the increase in concen‐
trations of some coagulation activation markers and fibrinolysis —tissue factor (TF), activated
factor VII, thrombin-antithrombin (TAT) complex, prothrombin fragment 1 + 2, fibrinopeptide
A, soluble fibrin-monomer complexes, and D-dimers. The latter plays a special role, consid‐
ering the experience of their wide use in clinical practice for the diagnosis of VTE and for
monitoring the efficiency of anticoagulant use.
D-dimers are known to be as a result of the sequential influence of thrombin, activated factor
XIII, and plasmin on fibrinogen [44–46]. The increase of D-dimer concentration is widely used
in the diagnostics as a laboratory criterion for activation of hypercoagulation and fibrinolysis,
under such human pathologies, as disseminated intravascular coagulation [47, 48], as well as
deep vein thrombosis of the lower extremity and pulmonary embolism [49, 50]. This parameter
is widely studied as a very effective step in the diagnostic algorithm for patients with suspected
first episode of PE or DVT [51]. There are many publications on the specificity and sensitivity
of this marker of hemostatic reactions for the diagnostics of VTE [52]. It should be noted that
the negative value of D-dimer allows the exclusion of VTE due to its high sensitivity of about
95% [53].
Recent studies in this field involve diagnostic use of age-adjusted D-dimer cutoff levels in adult
patients [17, 54]. To provide the most accurate diagnostics of VTE, besides D-dimer identifi‐
cation, it is suggested to take into account genetic susceptibility, inflammation, immune
characteristics, hemodynamic factors, as well as epigenetics profile or circulating levels of
microRNA [55–58]. In this regard, the role of biomarkers such as C-reactive protein, soluble
P-selectin, coagulation factor VIII activity, microvesicle containing tissue factor and white
blood cells as prospective candidates is considered [53, 59, 60]. The rationale behind the use
of these markers to diagnose VTE (except, D-dimers) remains unclear.
However, in this work, we were interested in a different, but no less important question, which
is not devoted to the diagnostics, but to the prevention of venous thrombosis—whose blood
coagulation activation marker is more acceptable for decision making to initiate heparin
prophylaxis and are used in case of confirmed VTE therapeutic doses of heparin. To find such
methodological approach, we suggest a return to the mechanism of anticoagulant action of
heparin and low molecular weight heparin (LMWH) analogues. Thrombin is a key enzyme of
the blood coagulation system; it is also a vitamin K-dependent protein related to the serine
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protease class. In the liver, there is a synthesis of its precursor—prothrombin, which is further
present in plasma and can be converted into α-thrombin by blood coagulation activation. This
transformation occurs in composition of factors Xa, Va, and II on the surface of activated blood
cell membranes and endothelium [61, 62]. LMWH is known to inhibit factors Xa and IIa
(thrombin) with plasma antithrombin, as well as to promote TFPI expression [63]. The total
result of these reactions is considered to be the decrease of high initial rate of thrombin
generation, which should be achieved in patients with thrombotic state of readiness.
An excessive thrombin generation can be determined, for example, by calibrated automated
thrombography (thrombin generation test, TGT) suggested by Hemker et al. [64, 65], which
allows measuring the dynamics of the formation and inactivation of thrombin with improved
accuracy. During thrombin generation test (with the use of fluorimeter and computer data
processing), the area under the curve and the peak rate are measured having an ascending
part, the area of achieving the maximum, and the descending part, which characterizes the
inactivation of the enzyme. This test captures the end result of a complex array of enzymatic
interactions involved in blood coagulation and reacts on any trend toward coagulation
activation in blood plasma, as a result, it has integrated nature. According to the opinion of a
number of authors [66–68], measurement of an individual’s capacity to generate thrombin,
which occur under the action of TF in vitro, may be a better indicator of blood coagulation
activation, compared to tests designed to study fibrin clot formation or determine potential
biomarkers—prothrombin fragment 1 + 2, fibrinopeptide A, TAT complex, and D-dimers.
Based on the opinion of other authors, we consider that excessive (related to reference interval)
thrombin generation can be accepted not only for the identification of blood coagulation
activation but also as an objective prerequisite for the prescription of prophylactic LMWH in
certain cases. At the same time, according to the recent International Consensus Statement [15],
prophylaxis of VTE in women with thrombophilia depends on the type of thrombophilia, and
also on other risk factors, such as age 35 years or more, personal or family history of VTE,
obesity, immobilization during pregnancy, multiparity, or gemellarity. Prophylaxis consist of
clinical surveillance, elastic compression stockings, and/or LMWH administration. It is often
decided on an individual basis, because randomized studies in this regard were not performed.
In contrast, to decide whether to use LMWH as thromboprophylaxis during pregnancy, we
consider the possible use of objective laboratory criteria. For this purpose, in our center
reference intervals, the dynamics of thrombin generation parameters were determined in the
blood plasma of 301 women during physiological pregnancy (full text of the article is presented
in the publication of 2016). This parameter was studied by means of flatbed fluorometer
Fluoroskan Ascent (ThermoFisher SCIENTIFIC). Tissue factor was used as an activator of
coagulation in a concentration of 5 pmol/l. Women were examined in a non-pregnant state, at
different stages of physiological pregnancy (6–8, 12–13, 22–24, 34–36 weeks of gestation) and
2–3 days after vaginal delivery.
As a result, during pregnancy, the acceleration of a parameter time to reach peak thrombin
(ttPeak) was determined in blood plasma, as well as changes of two other parameters used for
the assessment of thrombin generation intensity–peak thrombin and endogenous thrombin
potential (ETP, Figure 2). Since early pregnancy (6–8 weeks), the latter two parameters were
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on the increase (in comparison with pregravid period for peak thrombin by 55.1% and ETP by
39.6%) and correlated well with each other throughout pregnancy (Spearman correlation
coefficient 0.80; p < 0.001).
Figure 2. Box plots of reference intervals in pregravid period, at different stages of pregnancy, and in 2–3 days after
spontaneous labor for (a) time to reach peak thrombin, (b) peak thrombin, and (c) endogenous thrombin potential. In
figures, box plots represent the range of data from the 25th to 75th percentiles, while the bar in the middle of each box
plot represents the median value obtained excluding outliers. Circles indicate outliers (1.5 × the interquartile range)
and extreme values (3.0 × the interquartile range) outside the central box, respectively.
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In our opinion, exceeding the upper values of peak thrombin and/or ETP at different stages of
pregnancy can be considered as an objective prerequisite for the prescription of LMWHs,
irrespective of the causes or known personal thrombogenic risk factors (carriage of factor V
Leiden mutation, prothrombin mutation, deficiency of physiological anticoagulants, throm‐
botic history, and others). This approach was used for the initiation of heparin prophylaxis in
women who conceived after in vitro fertilization cycle, as an extension of the study published
earlier [69]. Another perspective research method for the assessment of thrombotic state of
readiness is the assessment of spatial fibrin clot growth (thrombodynamics). This integrated
method designed to study hemostatic system is based on the initiation of coagulation by means
of plasma contact with immobilized TF and monitoring fibrin clot spreading from activating
surface [70]. This method was widely used to study hemophilia, mechanisms of action of
antihemophilic drugs, and the development of new ones [71, 72]. There are some data about
the use of this method in pharmacology, such as the development of thrombin inhibitors [73],
a study of their antidotes [74], or study of the procoagulant activity of microparticles [75].
Clinical studies of the capacity of thrombodynamics to identify the development of procoa‐
gulant states are presented by the studies of patients with sepsis [76]. Further development of
this method (with the tentative title thrombodynamics 4D) has been presented in a number of
studies [77, 78]. The approach, based on videomicroscopy of fluorescence, produced by
thrombin-sensitive substrate, followed by a solution of an inverse reaction-diffusion problem,
allows not only observation of spatial clot growth but also the determination of thrombin as a
function of time and distance from the activator.
The appearance of these integrated methods represents undeniable progress in the field of
diagnostic improvement of a wide range of hemostatic disorders. They can be used in the
selection of risk group patients according to thrombotic and hemorrhagic complications, but
it is necessary to consider that, as a rule, only platelet-, erythrocyte-, and leukocyte-poor plasma
can be analyzed, which eliminates the influence of a blood cell component on the obtained
results.
5. Conclusion
In conclusion of this chapter, the following summary can be made. Nowadays, highlighted
thrombogenic risk factors in their prognostic value are often equal to different types of
thrombophilia; based on this, their separation loses its sense. We consider that any cause
promoting thrombus formation can be referred to as thrombogenic risk factors, which can
manifest itself or not, by thrombosis in patients throughout life. We suggest referring those
pathological states or syndromes, which manifested themselves as thrombotic events (e.g.,
antiphospholipid syndrome) to thrombophilia. It allows for a reduction in hyperdiagnostics
of thrombophilia and identifying patients with thrombophilia and patients in need of secon‐
dary thromboprophylaxis, taking into account their identified thrombogenic risk factors. We
consider that the presence of some thrombogenic risk factors, which have not manifested
themselves by thrombosis, is not a safe prerequisite for medicamental thromboprophylaxis.
From the point of view of personalized medicine, controllable risk factors should be identified
The Risk Factors of Thrombogenic, Thrombophilia, and the Principle for Heparin Prophylaxis in Personalized Medicine
http://dx.doi.org/10.5772/64118
59
in patients with the aim of elimination or modification, thereby reducing the likelihood of
thrombosis. On the other hand, the presence of enhanced thrombin generation or excessive
fibrin formation (in thrombodynamics test) among the manifestations of thrombotic state of
readiness can be referred to as objective reasons for the prescription of anticoagulants.
We hope that a consideration of the proposed approaches to the diagnostics of thrombophilia
and thromboprophylaxis will promote further development of preventative direction in this
field of medicine.
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